Media headlines about Pain Therapeutics (NASDAQ:PTIE) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pain Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.6601284159748 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Today’s Hot Mover – Pain Therapeutics, Inc., (NASDAQ: PTIE) – Stock Watch (stocksnewstimes.com)
- Health Care Sector Update for 10/30/2017: PTIE,CRME,COM.TO,PSTI – Nasdaq (nasdaq.com)
- Pain Therapeutics Announces Upcoming Meeting with FDA – GlobeNewswire (press release) (globenewswire.com)
- Analysts Set Expectations for Pain Therapeutics’ FY2017 Earnings (PTIE) (americanbankingnews.com)
A number of research firms have commented on PTIE. Zacks Investment Research downgraded shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Gabelli downgraded shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 17th.
Pain Therapeutics (PTIE) traded down 3.3598% during mid-day trading on Wednesday, reaching $3.4114. 103,074 shares of the company’s stock were exchanged. Pain Therapeutics has a 1-year low of $3.10 and a 1-year high of $9.31. The firm’s 50-day moving average is $4.09 and its 200 day moving average is $4.05. The stock’s market capitalization is $22.50 million.
Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.17). Analysts forecast that Pain Therapeutics will post ($2.20) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Pain Therapeutics (PTIE) Share Price” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/11/01/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-pain-therapeutics-ptie-share-price.html.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
What are top analysts saying about Pain Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pain Therapeutics and related companies.